Research progress on non-protein-targeted drugs for cancer therapy
Abstract Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer ther...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-023-02635-y |
| _version_ | 1797863219058966528 |
|---|---|
| author | Yiwen Zhang Lu Lu Feifeng Song Xiaozhou Zou Yujia Liu Xiaowei Zheng Jinjun Qian Chunyan Gu Ping Huang Ye Yang |
| author_facet | Yiwen Zhang Lu Lu Feifeng Song Xiaozhou Zou Yujia Liu Xiaowei Zheng Jinjun Qian Chunyan Gu Ping Huang Ye Yang |
| author_sort | Yiwen Zhang |
| collection | DOAJ |
| description | Abstract Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo. |
| first_indexed | 2024-04-09T22:33:12Z |
| format | Article |
| id | doaj.art-beea0966425145eaa28c40b588148adb |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-09T22:33:12Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-beea0966425145eaa28c40b588148adb2023-03-22T12:41:30ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662023-03-0142111910.1186/s13046-023-02635-yResearch progress on non-protein-targeted drugs for cancer therapyYiwen Zhang0Lu Lu1Feifeng Song2Xiaozhou Zou3Yujia Liu4Xiaowei Zheng5Jinjun Qian6Chunyan Gu7Ping Huang8Ye Yang9Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeSchool of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese MedicineSchool of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese MedicineCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical CollegeSchool of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese MedicineAbstract Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo.https://doi.org/10.1186/s13046-023-02635-yCancer therapyOligonucleotide drugsmRNA vaccinesTargetDelivery |
| spellingShingle | Yiwen Zhang Lu Lu Feifeng Song Xiaozhou Zou Yujia Liu Xiaowei Zheng Jinjun Qian Chunyan Gu Ping Huang Ye Yang Research progress on non-protein-targeted drugs for cancer therapy Journal of Experimental & Clinical Cancer Research Cancer therapy Oligonucleotide drugs mRNA vaccines Target Delivery |
| title | Research progress on non-protein-targeted drugs for cancer therapy |
| title_full | Research progress on non-protein-targeted drugs for cancer therapy |
| title_fullStr | Research progress on non-protein-targeted drugs for cancer therapy |
| title_full_unstemmed | Research progress on non-protein-targeted drugs for cancer therapy |
| title_short | Research progress on non-protein-targeted drugs for cancer therapy |
| title_sort | research progress on non protein targeted drugs for cancer therapy |
| topic | Cancer therapy Oligonucleotide drugs mRNA vaccines Target Delivery |
| url | https://doi.org/10.1186/s13046-023-02635-y |
| work_keys_str_mv | AT yiwenzhang researchprogressonnonproteintargeteddrugsforcancertherapy AT lulu researchprogressonnonproteintargeteddrugsforcancertherapy AT feifengsong researchprogressonnonproteintargeteddrugsforcancertherapy AT xiaozhouzou researchprogressonnonproteintargeteddrugsforcancertherapy AT yujialiu researchprogressonnonproteintargeteddrugsforcancertherapy AT xiaoweizheng researchprogressonnonproteintargeteddrugsforcancertherapy AT jinjunqian researchprogressonnonproteintargeteddrugsforcancertherapy AT chunyangu researchprogressonnonproteintargeteddrugsforcancertherapy AT pinghuang researchprogressonnonproteintargeteddrugsforcancertherapy AT yeyang researchprogressonnonproteintargeteddrugsforcancertherapy |